| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3999314 | Urologic Oncology: Seminars and Original Investigations | 2016 | 6 Pages |
Abstract
UCSI appears to be an independent prognostic factor of pT3 RCC and may be considered in future TNM systems to help stratify different prognoses. More attention should be paid to patients with pT3 RCC with UCSI and close follow-up is recommended to improve survival rates.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Luyao M.D., Xin M.D., Hongzhao M.D., Xintao M.D., Yu M.D., Yu M.D., Fan M.D., Yang M.D., Liangyou M.D., Yongpeng M.D., Lei M.D., Xu M.D.,